Paul G. Wyatt

List of Publications by Year
in descending order

92	6,162	71102	74163
papers	citations	41 h-index	75 g-index

100	100	100	8572
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases. ChemMedChem, 2008, 3, 435-444.	3.2	409
2	A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature, 2015, 522, 315-320.	27.8	353
3	Dihydropyrancarboxamides Related to Zanamivir:Â A New Series of Inhibitors of Influenza Virus Sialidases. 1. Discovery, Synthesis, Biological Activity, and Structureâ"Activity Relationships of 4-Guanidino- and 4-Amino-4H-pyran-6-carboxamides. Journal of Medicinal Chemistry, 1998, 41, 787-797.	6.4	324
4	Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. Journal of Medicinal Chemistry, 2008, 51, 4986-4999.	6.4	317
5	Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nature Reviews Microbiology, 2017, 15, 217-231.	28.6	315
6	Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. Journal of Medicinal Chemistry, 2009, 52, 379-388.	6.4	304
7	N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 2010, 464, 728-732.	27.8	272
8	A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLoS Biology, 2021, 19, e3001091.	5.6	163
9	Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay. Antimicrobial Agents and Chemotherapy, 2013, 57, 2913-2922.	3.2	135
10	Fragment-based hit identification: thinking in 3D. Drug Discovery Today, 2013, 18, 1221-1227.	6.4	132
11	Target assessment for antiparasitic drug discovery. Trends in Parasitology, 2007, 23, 589-595.	3.3	130
12	Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discoveryâ€. Journal of Medicinal Chemistry, 2007, 50, 2293-2296.	6.4	128
13	Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9318-9323.	7.1	119
14	Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6962-6965.	3.2	116
15	Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature, 2018, 560, 192-197.	27.8	112
16	Dihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein Crystallography. Journal of Medicinal Chemistry, 2011, 54, 6514-6530.	6.4	110
17	Prediction of Drug Penetration in Tuberculosis Lesions. ACS Infectious Diseases, 2016, 2, 552-563.	3.8	110
18	PE/PPE proteins mediate nutrient transport across the outer membrane of Mycobacterium tuberculosis. Science, 2020, 367, 1147-1151.	12.6	110

#	Article	IF	Citations
19	Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 140-152.	6.4	102
20	Target Validation: Linking Target and Chemical Properties to Desired Product Profile. Current Topics in Medicinal Chemistry, 2011, 11, 1275-1283.	2.1	99
21	One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening. Journal of Medicinal Chemistry, 2009, 52, 4454-4465.	6.4	96
22	Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7015-7020.	7.1	94
23	Detection of Ligands from a Dynamic Combinatorial Library by X-ray Crystallography. Angewandte Chemie - International Edition, 2003, 42, 4479-4482.	13.8	92
24	Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis. ACS Infectious Diseases, 2017, 3, 18-33.	3.8	77
25	Chemical Validation of Trypanothione Synthetase. Journal of Biological Chemistry, 2009, 284, 36137-36145.	3.4	68
26	Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. Journal of Medicinal Chemistry, 2016, 59, 9672-9685.	6.4	66
27	2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: identification, stereochemistry and initial SAR. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2579-2582.	2.2	65
28	Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma brucei N-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2014, 57, 9855-9869.	6.4	57
29	Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani. ACS Infectious Diseases, 2019, 5, 111-122.	3.8	55
30	Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies. PLoS ONE, 2021, 16, e0253364.	2.5	55
31	Investigation of Trypanothione Reductase as a Drug Target in Trypanosoma brucei. ChemMedChem, 2009, 4, 2060-2069.	3.2	54
32	Chemical Proteomic Analysis Reveals the Drugability of the Kinome of Trypanosoma brucei. ACS Chemical Biology, 2012, 7, 1858-1865.	3.4	53
33	Drug discovery in academia: the third way?. Expert Opinion on Drug Discovery, 2010, 5, 909-919.	5.0	52
34	2,5-Diketopiperazines as Potent, Selective, and Orally Bioavailable Oxytocin Antagonists. 2. Synthesis, Chirality, and Pharmacokinetics. Journal of Medicinal Chemistry, 2005, 48, 6956-6969.	6.4	50
35	2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structureâ€“Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization. ACS Infectious Diseases, 2018, 4, 954-969.	3.8	49
36	Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1405-1411.	2.2	47

#	Article	IF	Citations
37	De Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding Fragments. ACS Chemical Biology, 2013, 8, 1044-1052.	3.4	47
38	Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 669-673.	2.2	46
39	Synthesis and Evaluation of 1â€(1â€(Benzo[b]thiophenâ€2â€yl)cyclohexyl)piperidine (BTCP) Analogues as Inhibitors of Trypanothione Reductase. ChemMedChem, 2009, 4, 1341-1353.	3.2	45
40	Identification of Inhibitors of the Leishmania cdc2â€Related Protein Kinase CRK3. ChemMedChem, 2011, 6, 2214-2224.	3.2	45
41	Clinically relevant enhancement of human sperm motility using compounds with reported phosphodiesterase inhibitor activity. Human Reproduction, 2014, 29, 2123-2135.	0.9	44
42	Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB. Journal of Medicinal Chemistry, 2018, 61, 6592-6608.	6.4	43
43	Design, Synthesis and Biological Evaluation of Trypanosoma brucei Trypanothione Synthetase Inhibitors. ChemMedChem, 2012, 7, 95-106.	3.2	42
44	Structureâ€“activity relationship investigations of a potent and selective benzodiazepine oxytocin antagonist. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1301-1305.	2.2	41
45	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 8374-8389.	6.4	41
46	Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Bioorganic and Medicinal Chemistry, 2006, 14, 1255-1273.	3.0	40
47	Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma brucei Pteridine Reductaseâ€…1. ChemMedChem, 2011, 6, 302-308.	3.2	39
48	N-Myristoyltransferase Is a Cell Wall Target in Aspergillus fumigatus. ACS Chemical Biology, 2015, 10, 1425-1434.	3.4	38
49	Nuclear DBF-2-related Kinases Are Essential Regulators of Cytokinesis in Bloodstream Stage Trypanosoma brucei. Journal of Biological Chemistry, 2010, 285, 15356-15368.	3.4	35
50	Fragment library design, synthesis and expansion: nurturing a synthesis and training platform. Drug Discovery Today, 2017, 22, 43-56.	6.4	35
51	Targeting N-myristoylation for therapy of B-cell lymphomas. Nature Communications, 2020, 11, 5348.	12.8	35
52	Exploring the Trypanosoma brucei Hsp83 Potential as a Target for Structure Guided Drug Design. PLoS Neglected Tropical Diseases, 2013, 7, e2492.	3.0	34
53	Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2019, 62, 1180-1202.	6.4	33
54	Structureâ€“Activity Relationship Studies of Pyrrolone Antimalarial Agents. ChemMedChem, 2013, 8, 1537-1544.	3.2	32

#	Article	IF	Citations
55	The Tuberculosis Drug Accelerator at year 10: what have we learned?. Nature Medicine, 2021, 27, 1333-1337.	30.7	32
56	Antitumor Quinol PMX464 Is a Cytocidal Anti-trypanosomal Inhibitor Targeting Trypanothione Metabolism. Journal of Biological Chemistry, 2011, 286, 8523-8533.	3.4	31
57	Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi. Journal of Medicinal Chemistry, 2017, 60, 7284-7299.	6.4	31
58	Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1399-1404.	2.2	30
59	From Onâ€Target to Offâ€Target Activity: Identification and Optimisation of Trypanosoma brucei GSK3 Inhibitors and Their Characterisation as Antiâ€Trypanosoma brucei Drug Discovery Lead Molecules. ChemMedChem, 2013, 8, 1127-1137.	3.2	30
60	The Design and Synthesis of Potent and Selective Inhibitors ofTrypanosoma bruceiGlycogen Synthase Kinase 3 for the Treatment of Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2014, 57, 7536-7549.	6.4	28
61	Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei. Journal of Medicinal Chemistry, 2015, 58, 7695-7706.	6.4	28
62	Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2021, 64, 5905-5930.	6.4	25
63	A Target Repurposing Approach Identifies N-myristoyltransferase as a New Candidate Drug Target in Filarial Nematodes. PLoS Neglected Tropical Diseases, 2014, 8, e3145.	3.0	20
64	Development of Smallâ€Molecule Trypanosoma brucei Nâ€Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode. ChemMedChem, 2015, 10, 1821-1836.	3.2	20
65	Drug discovery for male subfertility using high-throughput screening: a new approach to an unsolved problem. Human Reproduction, 2017, 32, 974-984.	0.9	19
66	Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth. ACS Omega, 2021, 6, 2284-2311.	3.5	19
67	Discovery of super soft-drug modulators of sphingosine-1-phosphate receptor 1. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3255-3259.	2.2	18
68	Quinol derivatives as potential trypanocidal agents. Bioorganic and Medicinal Chemistry, 2012, 20, 1607-1615.	3.0	17
69	Setting Our Sights on Infectious Diseases. ACS Infectious Diseases, 2020, 6, 3-13.	3.8	17
70	The emerging academic drug-discovery sector. Future Medicinal Chemistry, 2009, 1, 1013-1017.	2.3	15
71	Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library. ChemMedChem, 2015, 10, 1809-1820.	3.2	15
72	Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target. Journal of Medicinal Chemistry, 2022, 65, 409-423.	6.4	15

#	Article	IF	Citations
73	Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 9790-9806.	6.4	14
74	Generation of Polar Semiâ€Saturated Bicyclic Pyrazoles for Fragmentâ€Based Drugâ€Discovery Campaigns.. Chemistry - A European Journal, 2018, 24, 10443-10451.	3.3	13
75	Screening a protein kinase inhibitor library against Plasmodium falciparum. Malaria Journal, 2017, 16, 446.	2.3	12
76	Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA. ChemMedChem, 2018, 13, 672-677.	3.2	10
77	Diversity-oriented synthesis of bicyclic fragments containing privileged azines. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 248-251.	2.2	10
78	Inhibition of CorA-Dependent Magnesium Homeostasis Is Cidal in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
79	Structureâ€“Activity Relationships of Pyrazolo[1,5-a]pyrimidin-7(4H)-ones as Antitubercular Agents. ACS Infectious Diseases, 2021, 7, 479-492.	3.8	9
80	Antitubercular 2-Pyrazolylpyrimidinones: Structureâ€“Activity Relationship and Mode-of-Action Studies. Journal of Medicinal Chemistry, 2021, 64, 719-740.	6.4	9
81	Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity. Journal of Medicinal Chemistry, 2020, 63, 9523-9539.	6.4	8
82	Ligand binding: evaluating the contribution of the water molecules network using the Fragment Molecular Orbital method. Journal of Computer-Aided Molecular Design, 2021, 35, 1025-1036.	2.9	8
83	Inhibiting Mycobacterium tuberculosis CoaBC by targeting an allosteric site. Nature Communications, 2021, 12, 143.	12.8	8
84	Optimisation of the Antiâ€Trypanosoma brucei Activity of the Opioid Agonist U50488. ChemMedChem, 2011, 6, 1832-1840.	3.2	7
85	A Continuous Flow Strategy for the Facile Synthesis and Elaboration of Semiâ€Saturated Heterobicyclic Fragments. European Journal of Organic Chemistry, 2019, 2019, 1341-1349.	2.4	6
86	2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagasâ€™ disease. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3025-3030.	2.2	5
87	Discovery of Soft-Drug Topical Tool Modulators of Sphingosine-1-phosphate Receptor 1 (S1PR1). ACS Medicinal Chemistry Letters, 2019, 10, 341-347.	2.8	5
88	Resistance of Mycobacterium tuberculosis to indole 4-carboxamides occurs through alterations in drug metabolism and tryptophan biosynthesis. Cell Chemical Biology, 2021, 28, 1180-1191.e20.	5.2	5
89	Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4â€²-Phosphopantothenoyl-<scp>l</scp>-cysteine Synthetase (CoaB) Activity. ACS Infectious Diseases, 2021, 7, 1666-1679.	3.8	3
90	Identification and structure solution of fragment hits against kinetoplastidN-myristoyltransferase. Acta Crystallographica Section F, Structural Biology Communications, 2015, 71, 586-593.	0.8	2

#	Article	IF	Citations
91	Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis. RSC Medicinal Chemistry, 2020, 11, 1168-1177.	3.9	2
92	Editorial [Hot Topic: Progress in Neglected Disease Drug Discovery (Guest Editors: Andrew L. Hopkins) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.1	0